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Abstract
The rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis around the world, including in
industrialized nations, poses a great threat to human health and defines a need to develop new, effective and inexpensive
anti-tubercular agents. Previously we developed a chemical systems biology approach to identify off-targets of major
pharmaceuticals on a proteome-wide scale. In this paper we further demonstrate the value of this approach through the
discovery that existing commercially available drugs, prescribed for the treatment of Parkinson’s disease, have the potential
to treat MDR and XDR tuberculosis. These drugs, entacapone and tolcapone, are predicted to bind to the enzyme InhA and
directly inhibit substrate binding. The prediction is validated by in vitro and InhA kinetic assays using tablets of Comtan,
whose active component is entacapone. The minimal inhibition concentration (MIC99) of entacapone for Mycobacterium
tuberculosis (M.tuberculosis) is approximately 260.0 mM, well below the toxicity concentration determined by an in vitro
cytotoxicity model using a human neuroblastoma cell line. Moreover, kinetic assays indicate that Comtan inhibits InhA
activity by 47.0% at an entacapone concentration of approximately 80 mM. Thus the active component in Comtan
represents a promising lead compound for developing a new class of anti-tubercular therapeutics with excellent safety
profiles. More generally, the protocol described in this paper can be included in a drug discovery pipeline in an effort to
discover novel drug leads with desired safety profiles, and therefore accelerate the development of new drugs.
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Introduction
Tuberculosis, which is caused by the bacterial pathogen
Mycobacterium tuberculosis (M.tuberculosis), is a leading cause of
mortality among infectious diseases. It has been estimated by the
World Health Organization (WHO) that almost one-third of the
world’s population, around 2 billion people, is infected with the
disease [1]. Every year, more than 8 million people develop an
active form of the disease, which subsequently claims the lives of
nearly 2 million. This translates to over 4,900 deaths per day, and
more than 95% of these are in developing countries [2]. In 2002,
the WHO estimated that if the worldwide spread of tuberculosis
was left unchecked, then the disease would be responsible for
approximately 36 million more deaths by the year 2020.
Despite the current global situation, anti-tubercular drugs have
remained largely unchanged over the last four decades [3]. The
widespread use of these agents, and the time needed to remove
infection, has promoted the emergence of resistant M.tuberculosis
strains. Multi-drug resistant tuberculosis (MDR-TB) is defined as
resistance to the first-line drugs isoniazid and rifampin. The
effective treatment of MDR-TB necessitates the long-term use of
second-line drug combinations, an unfortunate consequence of
which is the emergence of extensively drug resistant tuberculosis
(XDR-TB) – M.tuberculosis strains that are resistant to isoniazid plus
rifampin, as well as key second-line drugs, such as ciprofloxacin
and moxifloxacin. XDR-TB is extremely difficult to treat because
the only remaining drug classes exhibit very low potency and high
toxicity. The rise of XDR-TB around the world, including in
industrialized nations, imposes a great threat on human health,
therefore emphasizing the need to identify new anti-tubercular
agents as an urgent priority [4].
Currently, anti-infective therapeutics are discovered and
developed by either de novo strategies, or through the extension
of available chemical compounds that target protein families with
the same or similar structures and functions. De novo drug discovery
involves the use of high throughput screening techniques to
identify new compounds, both synthetic and natural, as novel
drugs. Unfortunately, this approach has yielded very few successes
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progression from early-stage biochemical hits to robust lead
compounds is commonly an unfruitful process. The identification
of both molecular targets that are essential for the survival of the
pathogen, and compounds that are active on intact cells, is a
challenging task. Even more formidable, however, is the
requirement for appropriate potency levels and suitable pharma-
cokinetics, in order to achieve efficacy in small animal disease
models [5]. These challenges are reflected in the high costs
involved in bringing new drugs to market. In fact, it has been
estimated that the successful launch of a single new drug costs
more than US$800 million [6].
Two alternative drug discovery strategies that circumvent
some of the challenges associated with de novo drug discovery are
the label extension and ‘piggy-back’ strategies, both of which are
widely employed for the discovery of novel therapeutics to treat
tropical diseases. Label extension is a fast-track approach that
involves the extension of the indications of an existing treatment
to another disease. Some of the most important anti-parasitic
drugs in use today, such as praziquantel for schistosomiasis, were
derived from the label extension process. The major advantages
of label extension are the significant reductions in cost and time
to market that can be achieved. Alternatively, when a molecular
target that is present in a pathogen is under investigation for
other commercial indications, it is possible to adopt the ‘piggy-
back’ strategy by utilizing the identified chemical starting points.
Examples of this approach include the anti-malarial screening of
a lead series of cysteine protease inhibitors for the treatment of
osteoporosis, and histone deacetylase inhibitors for use in cancer
chemotherapy [5].
One of the main aims of drug discovery is to develop safe and
effective therapeutic agents through the optimization of binding to
a specific protein target. In this way, undesirable effects resulting
from side scatter pharmacology are minimized. However, the
recent and rapid completion of numerous genome sequencing
projects has revealed that proteins involved in entirely different
biochemical pathways, and even residing in different tissues and
organs, may possess functional binding pockets with similar shapes
and physiochemical properties [7]. Therefore, chemical matter for
one target could be considered as the basis for leads for an entirely
different target. Recent work on large scale mapping of
polypharmacology interactions by Paolini et al. [8] revealed the
extent of promiscuity of drugs and leads across the proteome.
They discovered that around 35% of 276,122 active compounds in
their database had observed activity for more than one target.
Whilst the majority of these promiscuous compounds were found
to be active against targets within the same gene family, a
significant number (around 25%) had recorded activity across
different gene families.
The finding that so many drugs interact with more than one
target provided the rationale behind the selective optimization of
side activities (SOSA) approach recently developed by Wermuth
[9,10]. The SOSA approach involves the use of old drugs for new
pharmacological targets, which is a valuable concept considering
the finite number of small molecules that can be safely
administered to humans. The process itself involves screening a
limited number of structurally diverse drug molecules, and then
optimizing the hits so that they show a stronger affinity for the new
target and a weaker affinity for the original target(s). In this way, it
is possible to derive a whole panel of new active molecules from a
single marketed drug. Since the screened drug molecules already
have known safety and bioavailability in humans, the overall time
and cost of drug discovery is significantly reduced when compared
with de novo strategies.
We have developed a novel computational strategy to identify
off-targets of major pharmaceuticals on a proteome-wide scale
[11–15]. Our methodology extends the scope of the SOSA
concept effectively and systematically across gene families, and is
more likely to be successful in achieving the ultimate goal of
providing new drugs from old ones. Our chemical systems biology
approach proceeds as follows:
1. The binding site of a commercially available drug is extracted
or predicted from a 3D structure or model of the target protein
[13].
2. Off-targets with similar ligand binding sites are identified across
the proteome using an efficient and accurate functional site
search algorithm [11].
3. Atomic interactions between the putative off-targets and the
drug are evaluated using protein-ligand docking. Only those
off-targets that do not experience serious atomic clashes with
the drug are selected for further analysis.
4. The drug is further optimized to enhance its potency, selectivity
and ADME properties by taking into account both the primary
target and the off-targets across the genome.
Our approach essentially explores complex protein-ligand
interaction networks on a proteome-wide scale. The lead
compound can be discovered from all drug targets across different
gene families. Moreover, lead optimization can focus on
compounds with excellent safety profiles and known clinical
outcomes. In this way, our approach has the potential to increase
the rate of successful drug discovery and development, whilst
reducing the costs involved.
In the present study we demonstrate the efficiency and efficacy
of our chemical systems biology approach through the discovery of
safe chemical compounds with the potential to treat MDR-TB and
XDR-TB. The identified compounds are entacapone and
tolcapone. These drugs primarily target human catechol-O-
methyltransferase (COMT), which is involved in the breakdown
of catecholamine neurotransmitters such as dopamine. They are
used as adjuncts to treat Parkinson’s disease by increasing the
bioavailability of the primary drug levodopa, which is a substrate
of COMT. Entacapone and tolcapone are predicted to inhibit
Author Summary
The rise of multi-drug resistant (MDR) and extensively drug
resistant (XDR) tuberculosis around the world, including in
industrialized nations, poses a great threat to human
health. This resistance highlights the need to develop new,
effective and inexpensive anti-tubercular agents. Unfortu-
nately, conventional approaches have yielded very few
successes in the field of anti-infective drug discovery. It is a
challenge to design drugs with both efficacy and safety.
These challenges are reflected in the high costs involved in
bringing new drugs to market. It has been estimated that
the cost to launch a successful new drug is in excess of
US$800 million. We have developed a novel computational
strategy to systematically identify cross-reactivity between
different drug target families. In this paper we demon-
strate the strength of this approach through the discovery
that existing commercially available drugs prescribed for
the treatment of Parkinson’s disease have the potential to
treat MDR and XDR tuberculosis. The protocol described
herein can be included in a drug discovery pipeline in an
effort to accelerate the development of new drugs with
reduced side effects.
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essential for type II fatty acid biosynthesis and the subsequent
synthesis of the bacterial cell wall [16]. InhA is the target of the
anti-tubercular drugs isoniazid [17] and ethionamide [18]. Similar
to newly developed direct InhA inhibitors [3,19–21], entacapone
and tolcapone require no enzymatic activation to bind InhA. Thus
they may avoid the commonly observed resistance mechanism to
isoniazid and ethionamide that is exhibited by many MDR strains.
Our computational predictions have been partially validated by
demonstrating that the entacapone drug tablet Comtan inhibits
the growth of M.tuberculosis at the minimal inhibition concentration
(MIC99) of entacapone of 260.0 mM, well below the concentration
leading to neuroblastoma cellular toxicity. The direct inhibition of
InhA by entacapone is further confirmed by experimental enzyme
kinetic assays, in which Comtan is shown to reduce InhA activity
by up to 47% at the effective entacapone concentration of 80 mM.
Since entacapone has an excellent safety profile with few side
effects, it shows potential as a drug lead in the development of a
new class of anti-tubercular therapeutics with favorable ADME/
Tox properties.
Results
Co-factor and ligand binding site similarity between
COMT and InhA
Recently, Xie and Bourne developed a sequence order
independent profile-profile alignment (SOIPPA) algorithm [11],
which they subsequently used to detect common binding sites
among proteins unrelated in sequence and/or function. Their
studies implied an evolutionary relationship between the NAD-
binding Rossmann fold and several other fold classes, including
the SAM-binding domain of the SAM-dependent methyltransfer-
ases, through similarities between their co-factor binding sites. It is
interesting to note that both nicotinamide adenine dinucleotide
(NAD) and S-adenosyl methionine (SAM) include adenine as a
common molecular fragment. In fact, previous studies have shown
that adenine binding pockets from proteins lacking significant
homology will share common physiochemical properties [11].
These findings, plus the versatility of our method, form the basis
for the present study.
Entacapone and tolcapone are drugs that block the ligand
binding site of COMT, a member of the SAM-dependent
methyltransferase superfamily, in the presence of the SAM co-
factor. They are used as adjuncts in Parkinson’s disease therapy,
to prevent the metabolism of levodopa to 3-O-methyldopa,
therefore improving levodopa bioavailability and increasing its
delivery to the brain [22]. The dopamine precursor levodopa
has been the key drug for symptomatic treatment of Parkinson’s
disease for more than 30 years. Since COMT is a SAM-
dependent methyltransferase, it is possible that it may possess a
ligand binding pocket similar to those found in protein domains
belonging to the NAD-binding Rossmann fold, as their co-factor
binding sites are strikingly similar [11]. When entacapone and
tolcapone were docked into 215 NAD-binding proteins from
multiple species, the InhA enzyme from several different
organisms, including M.tuberculosis, was consistently highly ranked
(see Tables S1 and S2). Since InhA is the primary target of the
anti-tubercular drugs isoniazid [17] and ethionamide [18],
entacapone and tolcapone can potentially inhibit the InhA
ligand binding site directly. Indeed, alignment of the COMT
and InhA binding sites by the SOIPPA algorithm revealed
similarities in the positioning of both their co-factors and ligands
(Figure 1).
2D small molecule similarity between existing and
potential InhA inhibitors
As shown in Figure 2, the existing InhA inhibitor with the
greatest 2D similarity to entacapone is 3-(6-aminopyridin-3-yl)-N-
methyl-N-[(1-methyl-1H-indol-2-yl)methyl]acrylamide (AYM)
[23] (Tanimoto coefficient=0.155), whereas the existing InhA
inhibitor with the greatest 2D similarity to tolcapone is 3-[(acetyl-
methyl-amino)-methyl]-4-amino-N-methyl-N-[(1-methyl-1H-in-
dol-2-yl)-methyl]-benzamide (ZAM) [23] (Tanimoto coeffi-
cient=0.173) (see Table S3). Neither of their p-values (AYM;
0.065 and ZAM; 0.205) are significant at the 0.05 level, implying
that none of the investigated InhA inhibitors exhibit significant
molecular similarity to either entacapone or tolcapone. Therefore,
it is unlikely that ligand-based screening methods would be able to
identify entacapone and tolcapone as potential InhA inhibitors.
Docking existing and potential InhA inhibitors and drug-
like molecules into InhA and COMT
Table 1 shows the predicted binding affinities of entacapone
and tolcapone towards InhA. Since they fall within the range of
binding affinities exhibited by the known InhA inhibitors, this not
only provides a further implication of the cross-reactivity between
InhA and COMT, but also suggests that entacapone and
tolcapone are able to inhibit InhA directly.
Unfortunately it is difficult to identify entacapone as a lead
compound using conventional virtual screening because it is only
ranked at 15,892 and 9,719 by eHiTs and Surflex among 20,000
randomly selected drug-like molecules, respectively. While ad-
vanced virtual screening techniques such as the relaxed complex
scheme [24], which combines a docking algorithm with molecular
dynamics simulations, may improve the ranking of these potential
lead compounds [25], they demand significant computational
resources. Thus, SOIPPA, a ligand binding site similarity based
method, provides an efficient way of identifying potential drug-like
leads that have well-established pharmacokinetics and pharmaco-
dynamics properties.
Figure 1. Ligand binding site similarity between COMT and
InhA. COMT is show in green, its SAM co-factor is shown in purple, and
its ligand is shown in red. InhA is shown in blue, its NAD co-factor is
shown in orange, and its ligand is shown in yellow. Protein structures
were aligned using the SOIPPA algorithm.
doi:10.1371/journal.pcbi.1000423.g001
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InhA
Although the 2D similarities between entacapone and existing
InhA inhibitors have been shown to be statistically insignificant,
entacapone shares a similar molecular size and common
functional groups with several of the InhA inhibitors (see
Table 1). For example, entacapone and five of the InhA inhibitors
(468, 566, 641, 665 and 774) all possess a single benzene and
amide moiety. More importantly, the predicted binding poses of
the benzene ring and the amide bond of entacapone are similar to
those of the InhA inhibitors, with root mean square deviations
(RMSDs) of as little as 2.87A ˚ and 1.05A ˚, respectively (in the case
of 566). Although tolcapone does not share the same amide
moiety, the predicted binding pose of its benzene ring has an
RMSD of only 1.01A ˚ from that of 566, further demonstrating the
potential of these drugs as InhA inhibitors.
Previous studies have highlighted the necessity of the interaction
betweenthecatecholoxygensofCOMTinhibitorswithanMg
2+ion
in the active site [26]. From the predicted binding poses of
entacapone and tolcapone docked with InhA, three potential
interaction sites of Mg
2+, including the Asp110, Asp115, and
Glu210 residues of InhA, have been identified and are shown in
Figure 3. The closest residue, Glu210, is positioned at a distance of
13.23A ˚ from the nitrite group of entacapone, and at a distance of
11.54A ˚ fromthe nitritegroup oftolcapone(seeFigureS2).Although
it is possible that the conformation of the side chains may adjust to
Figure 2. 2D small molecule similarity between existing and potential InhA inhibitors. The p-value of the InhA inhibitor with the highest
2D similarity score (Tanimoto coefficient) to A) entacapone and B) tolcapone is shown against a density distribution of 15,000 background scores.
doi:10.1371/journal.pcbi.1000423.g002
Table 1. Docking existing and potential InhA inhibitors into InhA and COMT.
InhA inhibitor IC50 to InhA (nM) Docking score with InhA Docking score with COMT
Pyrrolidine carboxamide s3 .100,000 [20] 25.14+/21.33 26.10
468 23,120 [20] 26.57+/21.27 24.42
566 10,660 [20] 26.24+/20.92 23.96
Triclosan 1,000 [21] 26.34+/20.68 24.05
744 970 [20] 26.07+/21.28 25.47
665 890 [20] 25.18+/20.72 24.20
641 390 [20] 26.00+/21.51 25.92
GEQ 200 [19] 26.29+/21.61 24.45
5PP 17 [21] 25.99+/20.48 23.90
8PP 5 [21] 26.51+/20.95 24.04
Entacapone .80,000 24.91+/20.97 24.49
Tolcapone - 25.85+/20.74 24.68
The results of the eHiTs docking studies are shown. The mean and standard deviation of the docking scores of each molecule with nine different InhAs are given, and
docking scores with COMT are included as a comparison. The same docking studies using Surflex showed strong agreement (see Table S4).
doi:10.1371/journal.pcbi.1000423.t001
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distancemayhindertheformationofacoordinatebondbytheMg
2+
ion between the InhA active site and each of the two drugs.
Consistent with the predicted binding pose, enzyme kinetic assays
indicate that the addition of an Mg
2+ ion has no effect on the
inhibition of InhA by entacapone. This therefore provides us with
opportunities to optimize entacapone and tolcapone, by reducing or
removing their conjugation to the Mg
2+ ion, so that they exhibit a
weaker affinity for the original target COMT.
Comparison of logP and logD values between existing
and potential anti-tubercular drugs
The partition coefficient (logP) is the ratio of the concentrations
of an unionized compound in the two phases of a mixture of
octanol and water at equilibrium, whereas the distribution
coefficient (logD) is the ratio of the sum of the concentrations of
all forms of the compound (both ionized and unionized) in each of
the two phases. Since logD is pH dependent, the pH at which it
was measured is specified, as shown in Table 2. Entacapone and
tolcapone were discovered to have generally higher logP and logD
values than most of the existing anti-tubercular drugs investigated.
According to Lipinski’s rule of five [27], poor absorption or
permeation is more likely for compounds with a logP value of
greater than 5.0. Such compounds are considered non-drug-like
and are commonly filtered out in the early stages of drug
discovery. However, entacapone and tolcapone are prescribed
drugs and have been clinically tested with desired pharmacoki-
netics profiles. Indeed, entacapone can be rapidly absorbed with a
Tmax of approximately one hour (http://www.rxlist.com/comtan-
drug.htm). The high logP values of entacapone and tolcapone are
therefore acceptable regardless of Lipinski’s rule. Moreover, they
suggest that entacapone and tolcapone are more hydrophobic
than existing drugs, and would therefore pass more easily through
the M.tuberculosis cell envelope. Although entacapone demonstrates
poor solubility, dissolution enhancers such as croscarmellose
sodium are used in the formulation of Comtan [28]. This example
well illustrates that drug repurposing would accelerate drug
discovery and development by bypassing the time consuming
steps of ADME/Tox evaluation and drug formulation.
Antibacterial activity of entacapone and tolcapone
Entacapone and tolcapone were evaluated for their ability to
inhibit growth of M.tuberculosis using a 96 well microplate assay. A
99.0% reduction in growth was observed with concentrations of
between62.5 mg/mland125 mg/mlforeachdrug.Thesensitivityof
M.tuberculosistoentacaponewasconfirmedbyquantitativegrowthon
agar plates containing known amounts of the drug. The minimum
inhibitory concentration was between 62.5 mg/ml and 125 mg/ml
(Table 3), therefore confirming the result from the microplate assay.
Theseresultssupportthecomputationalpredictionsthatentacapone
and tolcapone have inhibitory activity against M.tuberculosis and may
therefore be considered as lead compounds.
Enzyme kinetic assay of direct inhibition of InhA by
entacapone
The ability of entacapone to directly inhibit InhA was evaluated
using enzyme kinetics. Due to the strong UV absorbance of
entacapone over a wide range of 300–400 nm (see Figure S4), and
the poor solubility of entacaponein water,the highest concentration
of Comtan that could be used in the assays was 90 mg/ml (the
corresponding concentration of pure entacapone is 24.9 mg/ml), at
whichconcentrationInhAisapproximately47%inhibited.Fittingof
the data in Table 4 to a dose response equation provided an IC50
value of 2463 mg/ml (79610 mM) (see Figure S3). Since Mg
2+ is
critical for entacapone and tolcapone to inhibit COMT,assays were
repeated in the presence of 5 mM Mg
2+ to explore whether or not
Figure 3. Binding pose analysis of entacapone with InhA. The eHiTs predicted binding pose of entacapone is compared with that of a native
InhA ligand. The native ligand is shown in yellow and entacapone is colored by element. The NAD co-factor is shown in orange. Distances between
the nitrite group of entacapone and surrounding aspartic acid and glutamic acid residues are labeled.
doi:10.1371/journal.pcbi.1000423.g003
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However,theinclusionofMg
2+intheassayhadnoeffectontheIC50
value for enzyme inhibition. The progress curve analysis for the
inhibition of InhA by Comtan shows that the UV absorbance is
linearly time-dependent up to one hour (see Figure S5), indicating
that entacapone is not a slow-onset inhibitor.
Discussion
The sharp contrast between the fatty acid biosynthetic pathway
in humans (FAS-I) and that found in prokaryotes (FAS-II) has
established this bacterial pathway as an attractive target for the
design of new antibacterial agents [20,29]. The FAS-II pathway in
M.tuberculosis is involved in the production of mycolic acids, which,
along with peptidoglycan and arabinogalactan, are central
constituents of the mycobacterium cell wall [2,29]. InhA catalyzes
the final, rate-determining step in the fatty acid elongation cycle by
converting trans-2-enoyl-ACP to acyl-ACP in an NADH-depen-
dent reaction [3]. This crucial regulatory enzyme is the primary
molecular target of isoniazid, which has been used as a frontline
anti-tubercular agent for the past 40 years [20,29]. As a pro-drug,
the activity of isoniazid is dependent on its activation by KatG, a
catalase/peroxidase enzyme. KatG oxidizes isoniazid to an acyl
radical that covalently binds to NADH, and functions as a potent
inhibitor of InhA. Unfortunately, it is this activation requirement
that allows M.tuberculosis to acquire resistance to the drug. Indeed,
mutations in the KatG gene account for around half of all
isoniazid-resistant clinical isolates [3]. Direct InhA inhibitors that
avoid this activation requirement are not susceptible to this
resistance mechanism [30]. Triclosan and the diazoborines are
well-known InhA inhibitors that do not require activation, but
unfortunately they are not suitable for human treatment due to
their respective poor solubility and toxicity [3]. However, a new
class of high affinity direct InhA inhibitors, consisting of alkyl
diphenyl ethers of triclosan derivatives, have been found to exhibit
activity against drug-resistant strains of M.tuberculosis [21]. In
addition to these alkyl diphenyl ethers, the arylamides [20,31],
indole-piperazines, pyrazole-based inhibitors [3], and indole-based
inhibitors [23,32], have recently been described as other classes of
direct InhA inhibitors.
Using a novel computational strategy we have predicted that
entacapone and tolcapone will directly inhibit InhA. Our
prediction was subsequently confirmed by in vitro antibacterial
and enzyme kinetic assays using Comtan tablets containing the
active component entacapone. Thus entacapone and tolcapone
are promising lead compounds against drug-resistant strains of
M.tuberculosis. These drugs are currently in clinical use, although
the association of tolcapone with hepatotoxicity has caused the
drug to be placed under strict regulation in the United States [33].
Entacapone, which is not associated with the same hepatotoxic
risks, is therefore more attractive as a drug lead. Interestingly, a
recent study showed that when patients suffering from Parkinson’s
disease were treated with rifampin and isoniazid, their condition
was observed to improve [34]. Since rifampin inhibits DNA-
dependent RNA polymerase, this observation implies cross-
reactivity between the M.tuberculosis InhA, the target of isoniazid,
and the drug targets of Parkinson’s disease, which is consistent
with our predictions that InhA inhibitors can also inhibit COMT.
Table 2. Comparison of logP and logD values between existing and potential anti-tubercular drugs or pro-drugs (marked by an
asterisk).
Drug logP logD (pH 2) logD (pH 5) logD (pH 7) logD (pH 9)
COMT inhibitor Tolcapone 3.12 3.12 2.40 0.81 0.53
Entacapone 1.95 1.94 1.59 20.04 20.63
First-line anti-tubercular drug Ethambutol 20.31 27.51 26.14 23.63 21.31
Isoniazid* 20.63 21.97 20.64 20.63 20.63
Pyrazinamide* 21.53 21.53 21.53 21.53 21.53
Rifampicin 2.06 20.07 0.62 2.06 0.65
Streptomycin 28.30 215.74 215.26 213.45 212.05
Second-line anti-tubercular drug Ciprofloxacin 21.38 22.04 21.84 21.38 21.71
Moxifloxacin 21.88 21.76 21.78 21.87 21.87
Aminosalicylic acid 0.81 0.54 20.39 22.15 22.53
Values were calculated using ChemAxon’s Calculator. Values calculated from another program ChemSilico Predict are shown in Table S5.
doi:10.1371/journal.pcbi.1000423.t002
Table 3. In vitro assay results for sensitivity of M.tuberculosis
to entacapone.
Entacapone concentration
(mg/ml)
Bacterial number
(cfu/ml)
Percentage
inhibition
None 3.5610
6 0.0
15.6 3.3610
6 6.0
31.2 2.5610
6 29.0
62.5 7.0610
6 80.0
125.0 ,100.0 .99.99
250.0 ,100.0 .99.99
doi:10.1371/journal.pcbi.1000423.t003
Table 4. InhA kinetic assay results for entacapone inhibition.
Entacapone (mg/ml) Percentage inhibition of InhA
2.5 10.7
6.2 23.4
12.3 35.5
24.9 47.0
doi:10.1371/journal.pcbi.1000423.t004
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upregulation of M.tuberculosis detoxification mechanisms that result
in its metabolism or efflux from the cell [21]. For instance,
triclosan has been shown to induce the expression of an aromatic
dioxygenase involved in the degradation of arenes. Since triclosan
consists of a diphenyl ether structure, it is thought that the
induction of this enzyme may serve to degrade, and hence
detoxify, triclosan [35]. The subsequent modification of triclosan
derivatives has led to high affinity alkyl diphenyl ether InhA
inhibitors that upregulate neither efflux pumps nor aromatic
dioxygenase [21]. Although gene transcription studies are required
to determine the ability of entacapone and tolcapone to cause
upregulation of the aromatic dioxygenase, it is speculated that the
strong electron-withdrawing nitrite groups of these drugs may
result in significantly lower reduction potentials, therefore making
them less prone to oxidation by this enzyme. The narrow ranges of
the MIC99 and the IC50 of Comtan support this hypothesis.
From our current experimental results, it is not possible to
determine the effect of the inactive ingredients in the Comtan
tablets (magnesium stearate, microcrystalline cellulose, hydroxy-
propyl methylcellulose, yellow iron oxide and red iron oxide,
titanium dioxide, sucrose, mannitol, hydrogenated vegetable oil,
polysorbate 80, glycerol 85%, croscarmellose sodium) on the
growth of M.tuberculosis. It is unlikely that the major formulations in
the Comtan tablets (magnesium stearate, microcrystalline cellu-
lose, hydroxypropyl methylcellulose, iron oxide, titanium dioxide,
sucrose) directly affect M.tuberculosis growth because they are the
same as the active ingredients found in anti-tubercular drugs such
as Rifater (isoniazid/pyrazinamide/rifampin combination tablet),
Rifamate (isoniazid/rifampin tablet), and Priftin, whose active
component is a rifamycin derivative (http://www.rxlist.com).
Other ingredients such as polysorbate 80 and croscarmellose
sodium are mainly used to enhance the dissolution and stability of
entacapone [28]. It will be particularly interesting if they are active
against the growth of M.tuberculosis, as they are commonly used
food and drug additives. We have observed that a higher
concentration of pure entacapone than that which is present in
Comtan is required to achieve the same rate of inhibition in the
InhA assay. Additional experiments such as X-ray crystallography
and mass spectroscopy need to be conducted in order to
investigate the precise mechanisms of action of Comtan and
entacapone against M.tuberculosis.
Although we have demonstrated that Comtan is active against
M.tuberculosis in vitro, further studies are required in order to
transform it into an anti-tubercular therapeutic. The active
component of entacapone in Comtan has an MIC99 for
M.tuberculosis of approximately 80 mg/ml (262 mM), and an
estimated IC50 value for InhA inhibition of above 80 mM.
However, it exhibits very low cellular toxicity, with no effect on
neuroblastoma cell lines that provide an in vitro model for high
throughput toxicity screening [36] at concentrations of up to
500 mM [37], thus making the concentration required for
M.tuberculosis inhibition not unreasonable for a lead compound.
The possibility that entacapone inhibits other enzymes besides
InhA cannot be excluded. From our initial studies of the ligand
binding site similarity network in the M.tuberculosis structural
genome, InhA is one of the most promiscuous proteins, having a
similar ligand binding site to more than 20 other enzymes [15].
This implies that an InhA inhibitor can potentially interact with
multiple targets. If it is proven in future studies that entacapone
can inhibit multiple targets simultaneously, the potential of
entacapone as an anti-tubercular drug is even more promising,
as ‘‘dirty’’ drugs lessen the likelihood of emergent resistance and
higher clinical efficacy than exquisitely selective drugs [38,39].
A further challenge is transforming entacapone into a
nanomolar inhibitor without impacting its ADME/Tox profile.
A series of direct InhA inhibitors with IC50’s ranging from 1 nM to
greater than 100 mM are available in the RCSB Protein Data
Bank (PDB) [40]. Thus it is possible to build reliable 3D QSAR
models in order to guide the lead optimization process. Since
entacapone has been in clinical use for many years, the
accumulated knowledge of its pharmacokinetics and pharmaco-
dynamics will be invaluable in predicting ADME/Tox properties
of the compound and its derivatives.
Conclusion
The continuing emergence of M.tuberculosis strains resistant to all
existing, affordable drug treatments means that the development
of novel, effective and inexpensive drugs is an urgent priority [3].
Our chemical systems biology approach to drug discovery revealed
that Comtan, with the active component entacapone, shows
potential for use as an anti-tubercular drug. Entacapone may
adopt different inhibition mechanisms from the first- and second-
line drugs that result in MDR and XDR M.tuberculosis strains.
Moreover, it has an excellent safety profile with few side effects,
and is commercially available. Therefore, entacapone can
potentially be used as a lead compound to develop a new class
of anti-tubercular drugs.
By integrating techniques from ligand binding site similarity,
small molecule similarity and protein-ligand docking, our chemical
systems biology approach is able to model protein-ligand
interaction networks on a proteome-wide scale. The systematic
use of small molecules to probe biological systems will provide us
with valuable clues as to the molecular basis of cellular functions,
and at the same time it will shift the conventional one-target-one-
drug discovery process to a new multi-target-multi-drug paradigm.
Methods
Ligand binding site similarity between COMT and InhA
Previously, the SOIPPA algorithm had revealed a highly
significant similarity (p-value=2.7e-5) between the NAD binding
site of the Rossmann fold and SAM binding site of the SAM
methyltransferases [11]. In order to identify similar ligand binding
sites adjunct to the co-factor binding site, further docking studies
were carried out on the ligand binding sites of proteins that bind
NAD as a co-factor. Freely available docking software eHiTs 6.2
[41] and Surflex2.1 [42] were selected due to their relatively fast
speed, high accuracy and ease of automation in large-scale
docking studies. It is worth noting that when preparing PDB files
for any of the docking studies, NAD and SAM co-factors were
added as one of residues of the protein chain.
215 non-redundant proteins with NAD co-factors were
downloaded from the RCSB Protein Data Bank (PDB) [40,43].
The ideal coordinates for entacapone and tolcapone were
downloaded from DrugBank [44]. Both Surflex and eHiTs were
used to dock both entacapone and tolcapone onto each of the 215
proteins, and the proteins that produced the highest docking scores
were investigated further. Enoyl-acyl carrier protein reductases
(InhAs) from several different organisms, including M.tuberculosis
and Toxoplasma gondii, were identified as proteins to which
entacapone and tolcapone showed favorable binding affinities
(see Tables S1 and S2). However, the M.tuberculosis InhA (PDB ID:
2H7M) is the focus of this paper due to its importance as a drug
target for the treatment of tuberculosis.
Unfortunately, the human COMT protein that is the drug
target of entacapone and tolcapone is absent from the RCSB PDB.
The only COMT structure available at the time of writing is that
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[45] search revealed that human and rat COMT share 81%
sequence identity without insertion or deletion. Moreover, their
functional site residues were found to share 100% identity (see
Figure S1). Therefore, rat COMT (PDB ID: 2CL5) was used as an
accurate representation of human COMT throughout this study.
The SOIPPA algorithm was used to align the 2H7M structure
with that of 2CL5 so that their respective NAD and SAM co-factor
binding sites were aligned. The aligned proteins were then
visualized using Accelrys DS Visualizer (http://www.accelrys.
com/products/downloads/ds_visualizer/).
2D small molecule similarity between existing and
potential InhA inhibitors
The RCSB PDB was queried for proteins with sequence
similarity to chain A of 2H7M, using an e-value cut off of 0.0001.
Between them, the resulting proteins bound a total of 22 different
InhA inhibitors (including the ligand of 2H7M). OpenBabel
(http://openbabel.org) was used to calculate the 2D small
molecule similarity between these InhA inhibitors and both
entacapone and tolcapone. In order to create background
distributions for comparison, all drug-like molecules were
downloaded from the ZINC database [46], and a subset of
20,000 molecules was extracted randomly. The 2D similarities of
each of these molecules to both entacapone and tolcapone were
calculated using OpenBabel, and density distributions of the scores
were plotted using R 2.5.0 [47]. P-values corresponding to the 2D
similarity scores of the 22 InhA inhibitors were subsequently
calculated from both density distributions (see Table S3).
Docking existing and potential InhA inhibitors onto InhA
and COMT
Nine M.tuberculosis InhA structures (PDB IDs: 1P44, 1P45,
2B36, 2B37, 2H7I, 2H7L, 2H7M, 2H7N and 2H7P) were
downloaded from the RCSB PDB. The ten inhibitors of these
InhAs (Ligands: Pyrrolidine carboxamide s3, GEQ, TCL, 5PP,
8PS, 566, 665, 641, 744 and 468) were downloaded from the
RCSB PDB as ideal coordinates. In addition, the ideal coordinates
of entacapone and tolcapone were generated using CORINA
(http://www.molecular-networks.com/online_demos/corina_demo.
html). All twelve molecules were docked onto the nine InhA
structures, as well as onto COMT using eHiTs and Surflex. The
mean and standard deviation of the docking scores of each molecule
with all ten of the InhAs were calculated, and the docking scores were
tabulated for comparison.
Binding pose analysis of potential InhA inhibitors with
InhA
Thepredictedbindingposesofentacaponeandtolcaponewiththe
various different M.tuberculosis InhAs were visualized and analyzed
usingAccelrysDSVisualizer.Distancesbetweenthenitritegroupsof
entacapone and tolcapone and the surrounding aspartic acid and
glutamicacidresiduesofInhAweremeasured.RMSDsbetweenthe
benzene rings and the amide bonds of entacapone and the native
ligands were calculated, in addition to the RMSDs between the
benzene rings of tolcapone and the native ligands.
Comparison of logP and logD values between existing
and potential anti-tubercular drugs
The ideal coordinates of entacapone, tolcapone, five first-line
anti-tubercular drugs (ethambutol, isoniazid, pyrazinamide, rifam-
picin and streptomycin) and three second-line anti-tubercular
drugs (ciprofloxacin, moxifloxacin and aminosalicylic acid) were
downloaded from DrugBank [44]. Both ChemAxon’s Calculator
from Marvin Beans (http://www.chemaxon.com/marvin) and
ChemSilico Predict (http://www.chemsilico.com) were used to
calculate a) the partition coefficient (logP) and b) the distribution
coefficient (logD) of all ten drug molecules.
In vitro assay for sensitivity of M.tuberculosis to
entacapone and tolcapone
In order to prepare stock solutions of each drug, one tablet of
Comtan (Sandoz) containing 200 mg of entacapone, and one
tablet of Tasmar (Valeant) containing 100 mg of tolcapone were
each ground to a fine powder and completely dissolved in
dimethylsulfoxide (DMSO). For the microplate assay, serial
dilutions of each drug were made in Middlebrook 7H9 media
supplemented with ADS (albumin, dextrose, and saline) and
Tween 80 [48] in a volume of 100 ml. A culture of M.tuberculosis
Erdman was grown to mid log in 7H9 plus ADS and Tween 80,
and adjusted to an optical density600 of 0.2. 100 ml of bacteria was
subsequently added to each well. The cultures were incubated for
14 days until the control wells containing only medium developed
a dense layer of bacteria. Wells were visually scored for the
amount of growth in comparison to the control wells. The dilution
of drug that produced almost complete inhibition of growth was
scored as MIC99. The agar plate assay was carried out as
previously described [48] using Middlebrook 7H9 plates supple-
mented with OADC and containing known amounts of entaca-
pone. In order to determine the MIC99, the number of bacteria
that grew in the presence of each concentration of entacapone was
compared with the number of bacteria that grew on the plate with
no drug.
InhA kinetic assays
Comtan (entacapone) tablets were ground into powder, and
dissolved in DMSO. Kinetic assays using trans-2-dodecenoyl-
Coenzyme A (DD-CoA) and wild-type InhA were performed as
described previously [49]. Reactions were initiated by addition of
InhA to solutions containing 250 mM NADH, 25 mM DD-CoA, 0
or 5 mM MgCl2 and inhibitor in 30 mM PIPES and 150 mM
NaCl, pH 6.8 buffer. IC50 values were calculated by fitting the
initial velocity data to equation 1;
y~100%= 1z I=IC50 ðÞ ½  ð 1Þ
where I is the inhibitor concentration and y is the percent activity.
Data analysis was performed using Grafit 4.0 (Erithacus Software
Ltd.). The IC50 curve fitting is shown in the Figure S3.
A progress curve was calculated in order to study the slow-onset
mechanism of inhibition of Comtan (entacapone). InhA activity
was monitored by adding the enzyme (10 nM) to assay mixtures
containing 8% V/V glycerol, 0.1 mg/ml BSA, 2% V/V DMSO,
300 mM DD CoA, 250 mM NADH, 200 mM NAD
+ and
inhibitors. Reactions were monitored until the progress curve
became linear, therefore indicating that the steady-state had been
reached. Subsequently, a low enzyme concentration and a high
substrate concentration were used to ensure that the depletion of
the substrates was minimal and would not affect the reaction rate,
so that the progress curve in the absence of inhibitors was linear.
Progress curve data were collected for up to 1 hour (see Figure S5).
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